Francisella Tularensis

The dosage for Francisella Tularensis is not measured in milligrams but in the concentration of viable organisms per milliliter.

• Standard Immunization: A single dose is typically administered percutaneously. The procedure involves placing a drop of the reconstituted vaccine (containing approximately $2 \times 10^9$ organisms/mL) onto the skin, usually the upper arm, and performing 15 to 30 rapid punctures with a sterile bifurcated needle.
• Booster Doses: The need for booster doses is determined by periodic skin testing or serological monitoring of antibody titers. If titers fall below a protective threshold, a re-vaccination may be indicated every 1-3 years depending on the level of ongoing risk.

Francisella Tularensis (LVS) is NOT approved for pediatric use. The safety and efficacy of this live attenuated strain have not been established in individuals under the age of 18. Due to the risk of disseminated infection and the developing nature of the pediatric immune system, use in children is generally contraindicated unless under extreme emergency protocols directed by public health authorities.

Renal Impairment

No specific dosage adjustments are provided for patients with renal impairment, as the agent is cleared by the immune system rather than the kidneys. However, severe renal disease may be associated with relative immunodeficiency, which requires a risk-benefit analysis.

Hepatic Impairment

There are no established guidelines for hepatic impairment. Because the liver is a component of the reticuloendothelial system that clears bacteria, patients with advanced cirrhosis should be monitored closely for signs of systemic dissemination.

Elderly Patients

Clinical trials for the LVS vaccine typically exclude individuals over 65. In elderly patients, 'immuno-senescence' (the natural aging of the immune system) may lead to a reduced protective response or an increased risk of local complications. Use in this population should be approached with extreme caution.

This medication is never self-administered. It must be administered by a healthcare professional trained in the scarification technique.

1. 1Preparation: The skin (usually the deltoid area) is cleaned with alcohol and allowed to dry completely. Alcohol must be absent, as it can kill the live bacteria in the vaccine.
2. 2Application: A drop of the vaccine is placed on the skin.
3. 3Scarification: The bifurcated needle is used to puncture the skin repeatedly. This is not a deep injection; it is intended to deposit the agent into the basal layer of the epidermis.
4. 4Aftercare: The site must be covered with a loose, breathable bandage. The patient must be instructed not to touch or scratch the site, as the live bacteria can be spread to other parts of the body (autoinoculation) or to other people.
5. 5Storage: The lyophilized product must be stored at ultra-low temperatures ($-20^°C$ or colder) and used immediately after reconstitution.

As this is typically a single-dose primary series, 'missed doses' are not common. If a scheduled booster is missed, it should be administered as soon as the risk of exposure is re-evaluated. There is no need to restart the series if a booster is delayed.

An 'overdose' in the context of a live vaccine involves the administration of too many CFUs or accidental systemic injection.

• Signs: Severe local ulceration, high fever, systemic tularemia-like symptoms (pneumonia, typhoidal symptoms), and significant lymphadenopathy.
• Emergency Measures: If systemic infection is suspected, immediate treatment with appropriate antibiotics (such as streptomycin, gentamicin, or ciprofloxacin) is required to kill the live vaccine strain. Supportive care for potential anaphylaxis or neuromuscular blockade must be available.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this agent without medical guidance.

Because Francisella Tularensis is a live attenuated vaccine, side effects are expected as part of the 'take' (the successful immune response).

• Injection Site Reactions: Nearly 100% of successful vaccinations result in a local lesion. This begins as a papule (small bump) within 3-5 days, progresses to a vesicle (blister), and then forms an eschar (scab). This process can be itchy and mildly painful.
• Regional Lymphadenopathy: Swelling of the lymph nodes in the armpit or neck on the side of the vaccination is very common. This indicates the immune system is responding to the agent.
• Malaise and Fatigue: A general feeling of being unwell, often lasting 24-48 hours after the 'take' becomes apparent.
• Low-grade Fever: Temperatures between $99^°F$ and $101^°F$ are frequently reported.

• Headache: Often described as a dull, throbbing sensation that responds to acetaminophen.
• Myalgia: Muscle aches, particularly in the back and limbs.
• Nausea: Mild gastrointestinal upset without significant vomiting.
• Large Local Reactions: Redness and swelling extending more than 5 cm from the puncture site.

• Autoinoculation: Accidental transfer of the live bacteria from the vaccination site to the eyes, nose, or other skin areas, leading to secondary lesions.
• Erythema Multiforme: A skin rash characterized by 'target' lesions, representing an immunologic hypersensitivity reaction.
• Secondary Bacterial Infection: The vaccination site may become infected with other bacteria (like Staph or Strep) if not kept clean.

> Warning: Stop taking Francisella Tularensis and call your doctor immediately if you experience any of these.

• Anaphylaxis: Signs include hives, swelling of the face or throat, difficulty breathing, and a rapid heartbeat. This is a medical emergency.
• Systemic Tularemia: If the attenuated strain causes a full-body infection, symptoms include high fever ($>103^°F$), severe cough, chest pain, and extreme exhaustion. This may occur in individuals with undiagnosed immune deficiencies.
• Neuromuscular Weakness: Given its classification as a Neuromuscular Blocker [EPC], any signs of drooping eyelids (ptosis), difficulty swallowing (dysphagia), or generalized muscle weakness must be reported immediately, as it may indicate an exaggerated pharmacological response to the acetylcholine release inhibition.
• Generalized Vaccinia-like Rash: A widespread rash that may indicate the body cannot contain the live agent.

• Scarring: The most common long-term effect is a small, permanent scar at the vaccination site, similar to a smallpox vaccine scar.
• Persistent Lymphadenopathy: In rare cases, lymph nodes may remain enlarged for several months.
• Chronic Hypersensitivity: Rare reports of lingering joint pain or skin sensitivity have been noted in clinical literature.

While Francisella Tularensis (LVS) may not have a traditional 'Black Box' in the same way as a commercial pharmaceutical, its Investigational New Drug (IND) status and CDC protocols carry equivalent weight:

WARNING: LIVE INFECTIOUS AGENT

• This product contains live Francisella tularensis bacteria. It is capable of causing infection if mishandled.
• RESTRICTED DISTRIBUTION: Only for use by authorized personnel in high-risk occupational settings.
• CONTRAINDICATED IN IMMUNOCOMPROMISED: Use in patients with HIV, cancer, or those taking immunosuppressive drugs can lead to fatal disseminated infection.
• PREGNANCY RISK: Live vaccines pose a theoretical risk to the fetus; avoid use in pregnant women unless the risk of wild-type tularemia outweighs the vaccine risk.

Report any unusual symptoms to your healthcare provider immediately.

Francisella Tularensis is a biological agent of significant clinical concern. It must be handled under Biosafety Level 2 (BSL-2) or higher conditions during preparation. Patients must be fully informed that they are receiving a live organism that will cause a localized, controlled infection. The site of administration is infectious until the scab falls off naturally.

No formal FDA black box warning exists for Francisella Tularensis in the traditional commercial sense, as it is primarily an investigational or military-use biological. However, the documentation provided by the CDC and the Department of Defense (DoD) emphasizes that disseminated tularemia can occur in individuals who are immunocompromised. It is strictly prohibited for use in individuals with primary or secondary immunodeficiencies, including those with HIV/AIDS, leukemia, lymphoma, or those undergoing radiation therapy.

• Allergic Reactions / Anaphylaxis Risk: Patients with known hypersensitivity to any component of the vaccine, including certain antibiotics used during the manufacturing process (such as streptomycin), are at high risk for anaphylaxis.
• Organ-Specific Risks:
• Hepatotoxicity: While rare, systemic dissemination can lead to granulomatous hepatitis.
• Nephrotoxicity: Not typically associated with this agent, though systemic infection can lead to secondary renal stress.
• Neuromuscular Effects: Because this agent is an Acetylcholine Release Inhibitor, patients with pre-existing neuromuscular disorders (such as Myasthenia Gravis or Lambert-Eaton Syndrome) may experience severe exacerbation of their condition. The inhibition of acetylcholine can lead to acute respiratory distress if the diaphragm is affected.
• Skin Conditions: Individuals with active eczema, atopic dermatitis, or other exfoliative skin conditions should not receive the vaccine, as they are at risk for 'eczema tularense,' a widespread and dangerous skin infection.

• Site Monitoring: The vaccination site must be checked by a healthcare provider at 7 and 14 days to confirm a 'take.'
• Lab Tests: For those working in high-risk labs, periodic serology (agglutination titers) is required to ensure ongoing immunity.
• Liver Function: If systemic symptoms occur, liver enzyme tests (ALT/AST) and bilirubin levels should be checked.

Patients should avoid driving or operating heavy machinery for at least 24 hours following administration, as the potential for syncope (fainting) or an acute inflammatory response (fever/chills) can impair reaction times and physical coordination.

Alcohol consumption should be avoided for 48 hours before and after vaccination. Alcohol can suppress the acute immune response required for the vaccine to be effective and may exacerbate the malaise and headaches associated with the 'take.'

There is no 'discontinuation' in the traditional sense for a single-dose vaccine. However, if a patient experiences a severe reaction to the first dose, they must never receive a booster. The immunological memory created by the first dose is permanent, and subsequent exposure to the agent (even in attenuated form) could trigger an exaggerated, life-threatening hypersensitivity response.

> Important: Discuss all your medical conditions with your healthcare provider before starting Francisella Tularensis.

• Antibiotics (Bactericidal/Bacteriostatic): Drugs such as ciprofloxacin, doxycycline, gentamicin, and streptomycin must NOT be taken for at least 14 days following vaccination. Since the vaccine is a live bacterium, these antibiotics will kill the agent before the immune system can respond, rendering the vaccine useless.
• High-Dose Corticosteroids: Prednisone (typically >20mg/day) or other systemic steroids inhibit the immune response and increase the risk of the attenuated strain spreading uncontrollably throughout the body.

• Chemotherapy Agents: Any drug that causes bone marrow suppression (neutropenia) will prevent the body from containing the Francisella tularensis infection at the site of scarification.
• TNF-Alpha Inhibitors: Drugs like adalimumab or etanercept, used for rheumatoid arthritis, significantly increase the risk of granulomatous infections, making the LVS vaccine potentially lethal.
• Neuromuscular Blockers: If a patient is taking other medications categorized as neuromuscular blockers (e.g., vecuronium, succinylcholine), the Acetylcholine Release Inhibitor properties of Francisella Tularensis may prolong the duration of muscle paralysis, leading to prolonged recovery times from anesthesia.

• NSAIDs (High Dose): While used to treat fever, very high doses of ibuprofen or aspirin might theoretically blunt the initial inflammatory signaling required for optimal T-cell activation.
• Other Live Vaccines: Administration of other live vaccines (like MMR or Yellow Fever) should either be done on the same day or separated by at least 4 weeks to prevent 'immune interference.'

• No specific food restrictions exist for Francisella Tularensis. However, maintaining adequate hydration is essential to manage the potential fever and malaise following vaccination.

• Echinacea and Elderberry: These are often used as 'immune boosters.' While not strictly contraindicated, their effect on the specific cellular immune response to F. tularensis is unknown and could theoretically lead to an exaggerated local inflammatory response.
• St. John's Wort: No known interaction with the vaccine's mechanism, but patients should always inform their doctor of all supplements.

• Tularemia Agglutination Test: Vaccination will cause a positive result on this test. This must be noted in the patient's medical record to prevent a false diagnosis of wild-type tularemia infection in the future.
• TB Skin Test (PPD): Live vaccines can occasionally cause a false-negative result on a tuberculosis skin test. It is recommended to perform TB testing either before or 4 weeks after the Francisella Tularensis vaccine.

For each major interaction, the management strategy is usually to delay vaccination until the interacting drug is cleared from the system or to avoid the interacting drug during the 2-4 week 'take' period.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Francisella Tularensis must NEVER be used in the following circumstances:

• Primary Immunodeficiency: Conditions such as DiGeorge syndrome, Wiskott-Aldrich syndrome, or severe combined immunodeficiency (SCID). The body lacks the T-cell machinery to stop the attenuated bacteria from replicating.
• Acquired Immunodeficiency: Patients with HIV/AIDS, particularly those with low CD4 counts, are at extreme risk for disseminated disease.
• Pregnancy: Due to the theoretical risk of transplacental transmission of a live bacterial agent and potential fetal harm.
• Eczema and Atopic Dermatitis: Even if the condition is not currently active, these patients have a skin barrier defect that can lead to life-threatening widespread infection.
• Anaphylaxis to Components: Any history of severe allergic reaction to the vaccine's stabilizers or the antibiotics used in its production.

• Acute Febrile Illness: Vaccination should be delayed until the patient has recovered from any current infection to ensure the immune system can focus entirely on the vaccine agent.
• Breastfeeding: It is unknown if the live bacteria can be transmitted through breast milk or via contact with the vaccination site. A risk-benefit analysis is required.
• Chronic Neuromuscular Disease: Conditions like Myasthenia Gravis require careful consideration due to the agent's classification as an Acetylcholine Release Inhibitor.

• Antibiotic Sensitivity: Patients allergic to aminoglycosides (like streptomycin) must be screened carefully, as trace amounts may remain from the manufacturing process.
• Vaccinia Sensitivity: While F. tularensis is a bacterium and Vaccinia is a virus, the scarification method and the 'take' process are similar; patients who had severe reactions to the smallpox vaccine should be monitored with extra care.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Francisella Tularensis.

Francisella Tularensis is generally categorized as Pregnancy Category X (or equivalent for live vaccines). There are no adequate and well-controlled studies in pregnant women. However, live bacterial vaccines are known to pose risks of infection to the fetus. In a public health emergency involving aerosolized tularemia, the risk of the disease to the mother may outweigh the risk of the vaccine, but under normal occupational circumstances, pregnancy is an absolute contraindication. Women of childbearing age should use effective contraception for at least one month following vaccination.

It is not known whether Francisella tularensis LVS is excreted in human milk. The primary risk to a nursing infant is not necessarily through the milk, but through direct contact with the infectious vaccination site on the mother's arm. If a breastfeeding woman must be vaccinated, the site must be covered with an occlusive dressing, and strict hand hygiene must be maintained to prevent accidental transmission to the infant.

As previously noted, this agent is not approved for use in children. The safety profile in the pediatric population is entirely unknown. In children, the risk of a live vaccine strain causing systemic illness is significantly higher than in adults. Tularemia in children is typically treated with antibiotics rather than prevented with the LVS vaccine.

Clinical data for patients over age 65 are extremely limited. Geriatric patients often have a diminished T-cell response, which could lead to a 'non-take' (failure to develop immunity) or a prolonged healing time for the vaccination eschar. Additionally, the Acetylcholine Release Inhibitor effects may be more pronounced in the elderly, who often have lower cholinergic reserves, potentially increasing the risk of confusion or muscle weakness.

No dosage adjustment is required. However, clinicians should be aware that end-stage renal disease (ESRD) is an immunocompromising condition. Patients on dialysis may have impaired cellular immunity, requiring a more cautious approach to live vaccine administration.

No specific adjustments are established. Since the liver plays a role in filtering systemic bacteria, any patient with significant hepatic dysfunction should be monitored for signs that the attenuated infection has moved beyond the regional lymph nodes.

> Important: Special populations require individualized medical assessment by a specialist in infectious diseases or immunology.

Francisella Tularensis (LVS) acts as a potent immunomodulator. Its primary molecular mechanism involves the activation of the Innate Immune System via Toll-like Receptor 2 (TLR2). Once the attenuated bacteria are internalized by antigen-presenting cells (APCs), they trigger the inflammasome, leading to the release of pro-inflammatory cytokines like IL-1β and IL-18.

Furthermore, its classification as an Acetylcholine Release Inhibitor suggests a secondary mechanism. In this pathway, components of the bacterium or its metabolic byproducts interfere with the calcium-triggered fusion of synaptic vesicles with the presynaptic membrane. By inhibiting the release of acetylcholine, the agent can modulate the 'cholinergic tone' of the host, which may have implications for both the immune response (via the cholinergic anti-inflammatory pathway) and neuromuscular function.

The dose-response relationship of Francisella Tularensis is binary: either a 'take' occurs, or it does not. The time to onset of the local lesion is 3-5 days, with peak immunological activity occurring between days 7 and 14. Protective antibody titers and T-cell memory are typically established within 21 to 28 days. Tolerance to the vaccine does not develop, but the immune system will 'reject' subsequent doses, preventing the bacteria from replicating upon re-exposure.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Percutaneous) |

| Protein Binding | N/A (Biological Agent) |

| Duration of Infection | 2 - 4 weeks |

| Tmax (Local Lesion) | 7 - 10 days |

| Metabolism | Macrophage Degradation |

| Excretion | Not Renally Excreted |

• Molecular Formula: N/A (Live Organism)
• Structure: Gram-negative coccobacillus, approximately 0.2 x 0.2-0.7 μm in size. It possesses a unique lipid-rich capsule that is essential for its ability to survive inside host cells.
• Solubility: Reconstituted in sterile saline or specialized stabilizing buffers.

Francisella Tularensis belongs to the class of Live Attenuated Bacterial Vaccines. It is unique among vaccines for its additional classification as an Acetylcholine Release Inhibitor [EPC] and Neuromuscular Blocker [EPC]. It is related to other live bacterial vaccines such as the BCG vaccine (for Tuberculosis) and the Typhoid live oral vaccine (Ty21a).